Immunotech Laboratories, Inc. is a drug development company. The company is headquartered in Glendale, California and currently employs 4 full-time employees. The company went IPO on 2002-01-07. The firm is also focused on the commercialization of its proprietary proteins known as Irreversible Pepsin Fraction (IPF) ITV-1 for the treatment of debilitating infectious diseases, such as human immunodeficiency virus (HIV) and Hepatitis Type C.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2005
12/31/2004
12/31/2003
12/31/2002
12/31/2001
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
0
--
--
--
--
--
Gross Profit
0
--
--
--
--
--
Selling, General & Admin
6
2
0
0
0
0
Research & Development
--
--
--
--
--
--
Operating Expenses
6
2
0
0
0
0
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
-41
-33
0
0
-1
0
Income Tax Expense
0
0
0
0
0
0
Net Income
-41
-33
0
0
-1
0
Net Income Growth
32%
--
--
-100%
--
--
Shares Outstanding (Diluted)
0.26
0.04
0
0
0
0
Shares Change (YoY)
1,540%
1,512%
18%
16%
6%
28.99%
EPS (Diluted)
-153.51
-802.19
-43.19
-278.28
-835.67
-425.42
EPS Growth
-92%
1,757%
-84%
-67%
96%
88%
Free Cash Flow
0
0
0
0
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
0%
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
-6
-2
0
0
0
0
EBITDA Margin
0%
0%
0%
0%
0%
0%
D&A For EBITDA
0
0
0
0
0
0
EBIT
-6
-2
0
0
0
0
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are Immunotech Laboratories Inc's key financial statements?
According to the latest financial statement (Form-10K), Immunotech Laboratories Inc has a total asset of $0, Net loss of $-33
What are the key financial ratios for IMMB?
Immunotech Laboratories Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is Immunotech Laboratories Inc's revenue broken down by segment or geography?
Immunotech Laboratories Inc largest revenue segment is Development Property, at a revenue of 257,125,468,039 in the most earnings release.For geography, China is the primary market for Immunotech Laboratories Inc, at a revenue of 302,280,996,891.
Is Immunotech Laboratories Inc profitable?
no, according to the latest financial statements, Immunotech Laboratories Inc has a net loss of $-33
Does Immunotech Laboratories Inc have any liabilities?
yes, Immunotech Laboratories Inc has liability of 1
How many outstanding shares for Immunotech Laboratories Inc?
Immunotech Laboratories Inc has a total outstanding shares of 0.15